Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
about
Profile of farletuzumab and its potential in the treatment of solid tumorsVintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.Targeting signaling pathways in epithelial ovarian cancer.Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy.Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.Vintafolide: a novel targeted agent for epithelial ovarian cancer.
P2860
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Population pharmacokinetics of ...... in epithelial ovarian cancer.
@ast
Population pharmacokinetics of ...... in epithelial ovarian cancer.
@en
type
label
Population pharmacokinetics of ...... in epithelial ovarian cancer.
@ast
Population pharmacokinetics of ...... in epithelial ovarian cancer.
@en
prefLabel
Population pharmacokinetics of ...... in epithelial ovarian cancer.
@ast
Population pharmacokinetics of ...... in epithelial ovarian cancer.
@en
P2093
P2860
P1476
Population pharmacokinetics of ...... in epithelial ovarian cancer.
@en
P2093
Charles Schweizer
Colm Farrell
Jason Wustner
Kenya Nakai
Martin D Phillips
Masayuki Namiki
Susan Weil
Tomohisa Nakano
P2860
P2888
P304
P356
10.1007/S00280-012-1959-Y
P577
2012-09-07T00:00:00Z